Dipeptidyl-peptidase-4 (DPP-4) inhibitor ameliorates 5-flurouracil induced intestinal mucositis

[1]  Chang Duck Kim,et al.  Ursodeoxycholic acid attenuates 5-fluorouracil-induced mucositis in a rat model. , 2018, Oncology letters.

[2]  Jae Min Lee,et al.  Selenium Administration Attenuates 5-Flurouracil-Induced Intestinal Mucositis , 2017, Nutrition and cancer.

[3]  C. Yeung,et al.  Amelioration of Chemotherapy-Induced Intestinal Mucositis by Orally Administered Probiotics in a Mouse Model , 2015, PloS one.

[4]  Tetsuhiro Tanaka,et al.  Anti-inflammatory role of DPP-4 inhibitors in a nondiabetic model of glomerular injury. , 2015, American journal of physiology. Renal physiology.

[5]  M. D. de Oliveira,et al.  S-Nitrosoglutathione Accelerates Recovery from 5-Fluorouracil-Induced Oral Mucositis , 2014, PloS one.

[6]  D. Mukherjee,et al.  Alogliptin; a review of a new dipeptidyl peptidase-4 (DPP-4) inhibitor for the treatment of type 2 diabetes mellitus. , 2014, Cardiovascular & hematological disorders drug targets.

[7]  S. Talwar,et al.  Inhibition of Caspases Protects Mice from Radiation-induced Oral Mucositis and Abolishes the Cleavage of RNA-binding Protein HuR* , 2013, The Journal of Biological Chemistry.

[8]  M. Martins,et al.  Effect of topical chamomile on immunohistochemical levels of IL-1β and TNF-α in 5-fluorouracil-induced oral mucositis in hamsters , 2013, Cancer Chemotherapy and Pharmacology.

[9]  J. Holst,et al.  Glucagon-like peptide-1 as a treatment for chemotherapy-induced mucositis , 2012, Gut.

[10]  J. Holst,et al.  The effect of glucagon-like peptide 1 on cardiovascular risk , 2012, Nature Reviews Cardiology.

[11]  W. Tissing,et al.  The Role of Intestinal Microbiota in the Development and Severity of Chemotherapy-Induced Mucositis , 2010, PLoS pathogens.

[12]  Carine Poussin,et al.  Glucagon-Like Peptide-1 Protects β-Cells Against Apoptosis by Increasing the Activity of an Igf-2/Igf-1 Receptor Autocrine Loop , 2009, Diabetes.

[13]  J. Bowen,et al.  New Pathways for Alimentary Mucositis , 2008, Journal of oncology.

[14]  S. Sonis,et al.  Emerging drugs for chemotherapy-induced mucositis , 2008 .

[15]  A. Assreuy,et al.  Gastrointestinal dysmotility in 5-fluorouracil-induced intestinal mucositis outlasts inflammatory process resolution , 2008, Cancer Chemotherapy and Pharmacology.

[16]  A. Karasik,et al.  Sitagliptin, a DPP-4 inhibitor for the treatment of patients with type 2 diabetes: a review of recent clinical trials , 2008, Current medical research and opinion.

[17]  A. Stringer,et al.  VSL#3 probiotic treatment reduces chemotherapy-induced diarrhoea and weight loss , 2007, Cancer biology & therapy.

[18]  D. Peterson,et al.  Treatment of mucositis, including new medications. , 2006, Cancer journal.

[19]  D. Peterson,et al.  Developing evidence-based guidelines for management of alimentary mucositis: process and pitfalls , 2006, Supportive Care in Cancer.

[20]  A. Hyatt,et al.  Rapid quantitative detection of chytridiomycosis (Batrachochytrium dendrobatidis) in amphibian samples using real-time Taqman PCR assay. , 2004, Diseases of aquatic organisms.

[21]  L. Elting,et al.  Perspectives on cancer therapy‐induced mucosal injury , 2004, Cancer.

[22]  S. Sonis.  The pathobiology of mucositis , 2004, Nature Reviews Cancer.

[23]  R. Perfetti,et al.  Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats. , 2002, Endocrinology.

[24]  R. Perfetti,et al.  The short half-life of glucagon-like peptide-1 in plasma does not reflect its long-lasting beneficial effects. , 2002, European journal of endocrinology.

[25]  A. Dorner,et al.  Defining mechanisms of action of interleukin-11 on the progression of radiation-induced oral mucositis in hamsters. , 2000, Oral oncology.

[26]  A. Komori,et al.  Expression Α Inhibition of Tumor Necrosis Factor a New Process of Cancer Prevention Mediated through Updated Version Citing Articles E-mail Alerts a New Process of Cancer Prevention Mediated through Inhibition of Tumor Necrosis Factor a Expression1 , 2013 .

[27]  H. Benko,et al.  The influence of serum tumor necrosis factor-alpha and interleukin-6 concentrations on nonhematologic toxicity and hematologic recovery in patients with acute myelogenous leukemia. , 1995, Experimental hematology.

[28]  S. Elad,et al.  Systematic review of agents for the management of gastrointestinal mucositis in cancer patients , 2012, Supportive Care in Cancer.

[29]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[30]  E. B. Jackson,et al.  Perspectives on , 1981, J. Am. Soc. Inf. Sci..